HTS-Compatible β-Lactamase Transcriptional Reporter Gene Assay for Interrogating the Heat Shock Response Pathway by Hancock, Michael K et al.
  Current Chemical Genomics, 2009, 3, 1-6 1 
 
  1875-3973/09  2009 Bentham Open 
Open Access 
HTS-Compatible -Lactamase Transcriptional Reporter Gene Assay for 
Interrogating the Heat Shock Response Pathway 
Michael K. Hancock
1, Menghang Xia
2, Elizabeth S. Frey
1, Srilatha Sakamuru
2 and Kun Bi*
,1 
1Invitrogen Corporation, Discovery Assays and Services, 501 Charmany Drive, Madison, WI 53719, USA 
2NIH Chemical Genomics Center, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20893, USA 
Abstract: Moderate environmental and physiological stressors are known to initiate protective heat shock response (HSR) 
leading to cell survival. HSR is largely mediated by the activation of heat shock factor (HSF), resulting in increased heat 
shock protein expression. Dysregulation of the HSR signaling has been associated with various diseases including cancer, 
inflammation and neurodegenerative disorders. Compounds that can modulate HSR have been pursued for the treatment 
of these diseases. To facilitate the discovery of HSR modulators, we developed a high-throughput amenable beta-
lactamase transcriptional reporter gene assay for monitoring the function of HSF. HeLa cells were engineered to express 
the beta-lactamase reporter under the control of HSF response elements (HSE) present in the HSP70 gene promoter. The 
HSE-beta lactamase (HSE-bla) reporter gene assay was validated by using HSF-specific siRNAs and known small mole-
cule modulators. Taking the advantage of fluorescence resonance energy transfer (FRET)-based cell permeable beta-
lactamase substrate, this assay can be miniaturized into 1536-well format. Our results demonstrate that the assay is robust 
and can be applied to high-throughput screening (HTS) for modulators of HSR. 
INTRODUCTION  
  Environmental and physiological stressors such as ele-
vated temperature, chemical toxicants and oxidative stress 
are known to induce heat shock response (HSR) leading to 
the increased expression of molecular chaperones such as 
heat shock proteins (HSPs) and other cytoprotective proteins 
[1]. HSR and the induction of HSPs are mediated by a family 
of transcription factors called heat shock factors (HSFs), 
which bind to the heat shock elements (HSEs) present in the 
promoter regions of HSP genes [1]. Among the three human 
HSFs, HSF-1, -2, and -4, HSF1 is the best characterized and 
essential for HSR [2]. Under normal conditions HSF1 exists 
as an inert monomer held in a repressed state, presumably by 
interaction with HSP90 and HSP70 [1, 3]. Upon exposure to 
stress, the rising level of unfolded proteins results in the dis-
sociation and derepression of HSF1. HSF1 then trimerizes, 
undergoes post-translational modifications, and accumulates 
in the nucleus where it activates HSP gene expression (Fig. 
1) [3].  
  Aberrations in HSR have been associated with various 
human diseases, such as neurodegenerative disorder, in-
flammation and cancer [4]. Small molecule modulators of 
HSR including those directly targeting HSP chaperones have 
been pursued for the treatment of these diseases [4]. For ex-
ample, HSP90 inhibitor 17-allylamino-17-demethoxygel-
danamycin (17-AAG) is currently in phase II clinical trial in 
patients with various cancers including melanoma and breast 
cancer [4]. Importantly, inhibition of HSP90 by 17-AAG 
also derepressses HSF1 and induces HSR [5]. Besides in-
hibitors of HSP90, proteasome inhibitors, amino acid ana- 
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logues, and molecules such as arachidonic acid and prosta-
glandins that induce inflammatory responses have been re-
ported to induce HSR [1, 4]. Such inducers of HSR may 
prove beneficial to counteracting the protein misfolding and 
aggregation associated with various neurodegenerative dis-
orders.  
  On the other hand, since tumor cells often express high 
levels of HSPs to survive the stressful environment in solid 
tumors, inhibitors of the HSR could be beneficial for cancer 
patients. Several inhibitors of the HSR have been reported. 
Quercetin (3,3’,4’,5,7-pentahydroxyflavone) is a natural 
compound that inhibits HSR in many cell types by down-
regulating HSF1 activity [6]. Benzylidene lactam KNK437 is 
reported to be a more selective compound that inhibits the 
expression of certain HSP family members [7]. Both quer-
cetin and KNK437 inhibit cancer proliferation and render the 
cells more sensitive to hyperthermia and chemotherapy [6, 
7]. Other reported inhibitors of HSR include triptolide, NZ28 
and emunin, each with different mechanisms of action [4]. In 
order to move forward for clinical development a significant 
effort needs to be invested to improve the potency and selec-
tivity of these compounds. 
  The lack of specific HSR modulators is partially due to a 
lack of robust cell-based assay tools for high-throughput 
screening. Here, we describe the development of a reporter 
gene assay for HSR applicable to high-throughput screening. 
HeLa cells were engineered to express the beta-lactamase 
reporter gene [8] under the control of HSF response elements 
present in the HSP70 gene promoter. The HSE-bla reporter 
cell line was validated using HSF1-specific siRNAs and 
known small molecule modulators, and the assay was minia-
turized into 1536-well format. Our results demonstrate that 
the assay is robust and can be applied to high-throughput 
screening for modulators of HSR. 2    Current Chemical Genomics, 2009, Volume 3  Hancock et al. 
PRINCIPLE OF ASSAY DESIGN 
  HeLa cells were transduced with lentivirus to express a 
beta-lactamase reporter gene under the control of three cop-
ies of HSE sequence (CTGGAATATTCCCGACCT 
GGCAG) present in the HSP70 gene promoter (Fig. 1). Cells 
expressing beta-lactamase after 42°C heat shock were iso-
lated using fluorescence-activated cell sorting (FACS). In its 
un-induced state HSF1 exists as an inert monomer that is 
presumably repressed by interactions with HSP90 and 
HSP70 (Fig. 1) [1, 3]. Heat shock or a known HSR inducer 
such as 17-AAG treatment leads to trimerization and phos-
phorylation of HSF1, which in turn binds to DNA response 
elements driving the expression of the downstream beta-
lactamase reporter gene (Fig. 1). Beta-lactamase activity can 
be detected by adding its substrate CCF4-AM directly into 
the cells [8, 9]. In the absence of HSR inducer the pathway is 
inactive, therefore there is little beta-lactamase expression. 
When the cells are loaded with CCF4-AM and are excited at 
406 nm, the substrate emits at around 530 nm (green). How-
ever, when cells are stimulated with 17-AAG the pathway is 
activated, leading to beta-lactamase reporter gene expres-
sion. The substrate is then cleaved by beta-lactamase, 
thereby disrupting the fluorescence resonance energy trans-
fer (FRET) and resulting in emission at 460 nm (blue) fol-
lowing excitation at 406 nm. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Diagram of the cell line design for HSR. 
 
METHODS 
Generation of the Stable HSE-bla Reporter Line 
  Three contiguous copies of the HSE sequence 
(CTGGAATATTCCCGACCTGGCAG) present in the 
HSP70 gene promoter was cloned into pLenti-bsd/MCS-bla 
vector (Invitrogen, Carlsbad, CA) via ClaI and NheI sites. 
Lentivirus was prepared according to the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA). HeLa cells were trans-
duced with the lentivirus expressing HSE-bla and selected 
for blasticidin resistance. Blasticidin resistant cells were left 
untreated or treated with heat shock at 42°C for 30 minutes, 
and then returned to 37°C. Cells were allowed to recover for 
4.5 hours and then loaded with CCF4-AM substrate for 2 
hours at room temperature prior to collecting a pool of heat 
shock induced beta-lactamase expressing cells by FACS. 
The cells were expanded and further tested in 384-well plate 
format for dose response using HSR inducer 17-AAG and 
HSF-specific RNAi knock-down. 
HSE-bla Assay in 384-well Plate Format 
  Cells in a sub-confluent state (or cryopreserved cells) 
were resuspended in Assay Medium (DMEM with Glu-
taMAX
TM (Invitrogen, Carlsbad, CA, catalog number 10569) 
supplemented with 0.1% dialyzed FBS, 0.1 mM NEAA, 25 
mM HEPES, 100 U/mL Penicillin and 100 g/mL Strepto-
mycin) and plated in a 384-well assay plate (Corning, 
Lowell, MA, catalog number 3712) at 8,000 cells (36 μL) 
per well (Table 1). 36 μL of Assay Medium without cells 
were plated in cell-free control wells on the same plate. Fol-
lowing overnight incubation at 37ºC, the cells were then 
stimulated with 4 L/well of 10x 17-AAG (LC Laboratories, 
MA, catalog number A-6880) over the indicated concentra-
tion range for 5 hours before adding 8 L/well of 6x Live-
BLAzer
TM-FRET B/G Substrate mixture (Invitrogen, catalog 
number K1096) for 2 hours. Fluorescence intensity at excita-
tion 406 nm and emission 460 nm and 530 nm were obtained 
using a Tecan Safire
2 fluorescence plate reader (Tecan, Dur-
ham, NC).  
Table 1.  Protocol for HSE-bla Assay in 384-well Plate Format 
Step Parameter  Value  Description 
1 HSE-bla Cells  36 μL 8,000  cells/well 
2 Incubation 16-18  hrs  37°C 
3 Compound  4  μL 17-AAG 
4 Incubation  5  hrs  37°C 
5 Substrate  8  μL CCF4-AM   
6  Incubation  2 hrs  Room Temp. 
7 Detection  fluorescence  Tecan  Safire
2 
 
  After subtracting the average fluorescence intensity from 
the cell-free control wells, the 460 nm/530 nm emission ratio 
was calculated. Response Ratio is a measurement of the as-
say window and is calculated as the 460 nm/530 nm emis-
sion ratio of the stimulated wells divided by the 460 nm/530 
nm emission ratio of the unstimulated wells. Response Ratio 
provides a consistent way for data comparison, especially 
when data generated from different plates are compared and 
when different plate reader settings are used which usually 
result in large variables in the 460 nm/530 nm emission ra-
tio. Response Ratios were plotted against test ligand concen-
trations in log scale and then analyzed using Prism software 
(GraphPad Software, Inc. San Diego, CA). A sigmoidal 
dose-response equation with varying slope was used to fit 
the data and generate EC50 values.  Z’-factor values were 
calculated as: Z’-factor = 1 - [(3 x stdevunstim + 3 x stdevmax-
stim) / (avgmaxstim – avgunstim)]. 
  For the compound inhibition experiment, cells were 
seeded into a 384-well assay plate at 8,000 cells (32 μL) per 
well. Following overnight incubation at 37°C, cells were 
pretreated for 1 hour with 4 L of quercetin (Sigma-Aldrich, 
Saint Louis, MO) at various final concentrations from 0.01 
to 200 M. Cells were then stimulated with 4 L of 17-AAG 
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at a final concentration of 65 nM (EC80) for 5 hours before 
the beta-lactamase assay was performed as described above. 
HSE-bla Assay in 1536-well Plate Format 
  Assay protocol is described in Table 2. Briefly, HSE-bla 
HeLa cells were resuspended in OPTI-MEM
® I medium (In-
vitrogen, CA, catalog number 51895) containing 0.1% dia-
lyzed FBS, and dispensed at 1500 cells/5 μL/well in 1536-
well black wall/clear bottom plates (Kalypsys, San Diego, 
CA) using a Flying Reagent Dispenser (Aurora Discovery, 
Carlsbad, CA). After the cells were incubated at 37ºC over-
night, 23 nL of DMSO or 17-AAG at concentration range of 
0.1 nM to 3.83 M was transferred to the assay plate by a 
pin tool (Kalypsys, San Diego, CA) resulting in a 217-fold 
dilution. The plates were incubated at 37°C for 6 hours. Af-
ter 1 L of LiveBLAzer
™ B/G FRET substrate (Invitrogen, 
Carlsbad, CA) was added, the plates were incubated at room 
temperature for an additional 2 hours and then fluorescence 
intensity at 405 nm excitation and 460 nm and 530 nm emis-
sion was measured using an Envision plate reader (Perkin 
Elmer, Shelton, CT). Data was expressed as the ratio of 460 
nm/530 nm emissions without background subtraction. 
Table  2.  Protocol for HSE-bla Assay in 1536-well Plate   
Format 
Step Parameter  Value  Description 
1 HSE-bla Cells  5 μL 1500  cells/well 
2 Incubation  16-18  hrs  37°C 
3  Compound  23 nL  17-AAG or DMSO 
4 Incubation  6  hrs  37°C 
5 Substrate  1  μL CCF4-AM   
6  Incubation  2 hrs  Room Temp. 
7 Detection fluorescence  Envision 
 
RNAi Experiment 
 HSE-bla HeLa cells were plated in 384-well format in 
Growth Medium (DMEM containing 10% dialyzed FBS, 0.1 
mM NEAA and 25 mM HEPES) at 2,000 cells/well and re-
verse transfected using Lipofectamine
TM RNAiMAX Trans-
fection Reagent (Invitrogen, Carlsbad, CA) and 20 nM of 
Stealth™ RNAi duplexes against HSF1, HSF2, and HSF4. 
RNAi oligo targeting beta-lactamase was used as the positive 
control and a random-sequence oligo with 48% GC content 
(MedGC) as the negative control. A set of 2 oligos for each 
HSF was used:  
HSF1-1(GGAUGCUAUGGACUCCAACCUGGAU) 
HSF1-2(UGCGGCAGCUCAACAUGUAUGGCUU) 
HSF2-1(GCAUAGACCCAGAUCUCCUGGUUGA) 
HSF2-2 (CCCUUUGGAAGGAGGUGUCAGAAUU) 
HSF4-1 (GGUCAUUGGCAAGCUGAUCCAGUGU) 
HSF4-2 (CCCUACUUCAUCCAGUCGCCUUCUA) 
  Cells were incubated with RNAi oligos at 37°C for 40 
hours, followed by a medium change to Assay Medium and 
then stimulation with 17-AAG for 6 hours before the beta-
lactamase assay was performed as described above. For heat 
shock treatment, 40 hours post-transfection the plate was 
subjected to heat shock at 42°C for 1 hour followed by a 5-
hour incubation at 37°C prior to performing the beta-
lactamase assay. 
RESULTS AND DISCUSSION 
Assay Development  
  To generate a cell-based assay suitable for high-
throughput screening for modulators of HSR, we stably inte-
grated an HSF-responsive beta-lactamase reporter element, 
HSE-bla, into the HeLa human cervical cancer cell back-
ground as detailed in Methods. Previous studies have estab-
lished that HeLa cells respond to heat shock leading to the 
activation of HSF1 and therefore serve as a suitable cell 
background for interrogating this pathway [10]. Following 
antibiotic selection, a highly responsive pool of stable inte-
grants was isolated that provides an effective HSR readout, 
with low beta-lactamase activity detected from unstimulated 
cells (i.e. mostly green cells) and efficient induction (i.e. 
mostly blue cells) observed following incubation at 42°C or 
by using HSP90 inhibitor 17-AAG (Fig. 1 and Fig. 2A). 
A Response to Known HSR inducers 
 
 
 
 
 
 
 
 
B 17-AAG Dose Response 
 
 
 
 
 
 
 
 
Fig. (2). HSE-bla HeLa cells respond to HSR inducers and heat 
shock.  (A)  HSE-bla HeLa cells were left untreated (unstim), or 
treated with 17-AAG (0.45 μM), Celastrol (1 μM) and Bortezomib 
(10 μM) for 5 hour, or incubated at 42°C for 1 hour and then recov-
ered for 5 hours in a 37°C/5% CO2 incubator before the beta-
lactamase assay was performed as described in Methods. Response 
Ratios were plotted for each condition (n=4 for each data point). 
(B) Dividing or cryopreserved HSE-bla HeLa cells were resus-
pended in Assay Medium and plated out in 384-well format as de-
scribed in Methods. Following an overnight incubation at 37°C, the 
cells were treated with the indicated concentrations of 17-AAG for 
5 hours before the beta-lactamase assay was performed as described 
in Methods. The calculated EC50 value for 17-AAG was 49 nM for 
dividing cells, and 36 nM for cryopreserved cells (n=4 for each data 
point). 
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 HSE-bla HeLa cells responded to 17-AAG in a dose de-
pendent manner with an EC50 value of 49 nM (Fig. 2B), con-
sistent with literature results [5]. At the highest two concen-
trations tested, a slight drop of response ratio was observed, 
presumably due to the negative feedback signal since no 
significant cytotoxicity was observed at these concentrations 
of 17-AAG. It is possible that high concentration of 17-AAG 
leads to high expression of HSP70 which then sequesters 
HSF1 from activating downstream reporter gene expression. 
 The  HSE-bla HeLa cells were also shown to be respon-
sive, to a lesser extent, to additional HSR inducers such as 
the triterpenoid antioxidant celastrol and proteasome inhibi-
tor bortezomib (Fig. 2A), consistent with previously reported 
activities for these inducers [1, 3]. 
  Assay-ready cryopreserved cells have recently become 
an important option for HTS, which demands a large quan-
tity of cells that can provide consistent assay results [11]. To 
further test the suitability of the HSE-bla HeLa cells for HTS 
applications, cryopreserved cells were thawed and immedi-
ately used for setting up the assay. A nearly super-imposable 
17-AAG dose response curve (EC50 of 36 nM) to that gener-
ated with dividing cells was obtained (Fig. 2B). The Z’ val-
ues at the maximum assay window for both dividing and 
cryopreserved cells were 0.83 and 0.88, respectively, indicat-
ing that cryopreserved assay-ready HSE-bla HeLa cells can 
be generated and applied for HTS. 
RNAi Validation 
  HSF1 is known to be essential for HSR induced by vari-
ous stressors [1]. To validate the assay and to determine 
which HSF is required for HSR in the HSE-bla HeLa cell 
line, RNAi experiments were performed where the effect of 
HSF-specific RNAi oligos on 17-AAG or heat shock-
induced beta-lactamase reporter activity was studied (Fig. 3). 
A beta-lactamase specific RNAi oligo (b-lac) was used as a 
positive control, which resulted in complete knock down of 
the reporter activity induced by both 17-AAG (Fig. 3A) and 
42°C heat shock (Fig. 3B). In contrast, the negative control 
oligo (MedGC) with random sequence and medium GC con-
tent showed minimal effects. Two RNAi oligos directed at 
HSF1 effectively blocked reporter activity to a similar extent 
as the beta-lactamase positive control under both of these 
HSR conditions. RNAi oligos against HSF2 and HSF4 did 
not show significant effect on the HSR reporter activity. 
These results suggest that HSF1 is essential for HSR reporter 
activity in HSE-bla HeLa cells, consistent with previous 
findings [2]. Moreover, these results also demonstrate the 
suitability of this reporter line for RNAi-mediated screening 
for HSR modulators. 
Inhibitor Activity  
  To demonstrate screening for inhibitors of HSR signal-
ing, dose response inhibition was performed using the fla-
vonoid quercetin, which has been reported to inhibit HSR by 
down-regulating HSF1 activity [6]. As shown in Fig. (4), 
quercetin effectively inhibited 17-AAG treated HSE-bla 
HeLa cells with an IC50 of 5.8 μM, suggesting that this assay 
can be used to screen for HSR inhibitors. 
 
 
 
 
 
 
 
 
Fig. (4). Inhibition of 17-AAG-induced beta-lactamase reporter 
activity in the HSE-bla HeLa cells. Cells were pretreated with the 
indicated concentrations of quercetin and then stimulated with 65 
nM 17-AAG for 5 hours before the beta-lactamase assay was per-
formed as described in Methods. Response Ratios were plotted for 
the indicated concentrations of quercetin (n=4 for each data point). 
The calculated IC50 for quercetin was 5.8 μM. 
 
Assay Optimization 
  To optimize the assay for 384-well format, several pa-
rameters were evaluated, including cell plating density, 
A. 17-AAG Stimulation 
 
 
 
 
 
 
 
 
B. Heat Shock Treatment 
 
 
 
 
 
 
 
 
Fig. (3). Effects of various HSF-specific RNAi oligos on 17-AAG 
and heat shock-induced beta-lactamase reporter activity. (A) Cells 
were incubated with the indicated RNAi oligos for 40 hrs, followed 
by a medium change to Assay Medium. Cells were then stimulated 
with 400 nM 17-AAG for 6 hours before the beta-lactamase assay 
was performed as described in Methods. (B) Cells were incubated 
with the indicated RNAi oligos for 40 hrs, followed by heat shock 
at 42°C for 1 hour and a 5-hour recovery at 37°C before the beta-
lactamase assay was performed as described in Methods (n=3 for 
each data point). Controls were as follows: nontransfected and un-
stimulated cells (NT unstim), nontransfected and stimulated cells 
(NT stim), mock transfected (mock), Stealth™ RNAi Negative 
Control Med GC (MedGC), and beta-lactamase positive control 
RNAi duplex (b-lac).  
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DMSO tolerance, 17-AAG stimulation time, and beta-
lactamase substrate loading time. First, the effect of cell den-
sity on assay performance was tested using a range of plating 
densities, from 2,000 cells/well to 16,000 cells/well (Fig. 
5A). A robust assay window was observed with a wide range 
of cell plating densities, from 4,000 cells/well to 12,000 
cells/well with EC50 values of 17-AAG ranging from 33 nM 
to 47 nM. The 8,000 cells/well plating density was selected 
as the basis for further assay optimization because it pro-
vided both a good assay window (7-fold) and minimal vari-
ability as exemplified by a CV (coefficient of variation) of 
5% at the maximal response. 
  To satisfy the HTS requirement for compounds to be 
dissolved in DMSO, a cell-based assay needs to be tolerant 
to certain amounts of DMSO. DMSO tolerance testing re-
sults (Fig. 5B) indicated that the HSE-bla HeLa reporter as-
say can tolerate up to 0.5% final DMSO concentration with 
only a modest drop in assay window (from ~7.2-fold in the 
presence of 0.1 % DMSO to ~5.2-fold in the presence of 
0.5% DMSO in this experiment). The highest concentration 
of DMSO (1%) tested adversely affected the reporter assay 
by reducing the assay window by nearly two-fold and pro-
ducing a substantial right-shift in the 17-AAG EC50 value. 
Thus, 0.1% DMSO was consistently used in all other assay 
optimization experiments described here. 
  It usually takes a minimum of 4 to 5 hours of ligand 
stimulation to activate downstream gene transcription. De-
pending on the pathway, longer stimulation may be required 
for generating a robust assay window. To test the effect of 
17-AAG stimulation time on assay performance, HSE-bla 
HeLa cells were stimulated with 17-AAG for 4, 6, or 16 
hours prior to assaying beta-lactamase activity (Fig. 5C). 
Among the three time points tested, a 6-hour incubation with 
17-AAG resulted in the highest response with a maximal 
response ratio of ~7.9, nearly two-fold higher as compared to 
the shorter 4-hour incubation (maximal response ratio of 
~4.0). Overnight incubation with 17-AAG resulted in a sub-
stantially diminished assay window (maximal response ratio 
of ~2.0). 
  The last parameter evaluated was the beta-lactamase sub-
strate loading time. It is known that when the amount of 
beta-lactamase present in cells is low, longer substrate load-
ing can result in more substrate conversion [8]. To evaluate 
the effect of substrate loading time on the HSR assay out-
come, an assay plate was read at various time points follow-
ing addition of the substrate to the wells (Fig. 5D). Increas-
ing substrate loading time clearly resulted in marked in-
creases in assay window up to a maximum of 3 hours of 
loading tested. Both 1.5-hour and 2-hour loading conditions 
generated sufficient assay windows and good Z’ values 
(0.80). Together a 5-hour 17-AAG stimulation and a loading 
     A.  Cell  Plating  Density      B.  DMSO  Tolerance 
 
 
 
 
 
 
 
 
      C. 17-AAG Stimulation Time       D. Substrate Loading Time 
 
 
 
 
 
 
 
 
 
Fig. (5). Assay optimization and performance testing in 384-well format. (A) Cell plating density testing. The assay was performed by plat-
ing 2,000 cells/well (), 4,000 cells/well (), 8,000 cells/well (), 12,000 cells/well (), and 16,000 cells/well (). Response ratios were 
plotted against 17-AAG concentration. Data are mean ± SE of n = 4 values. (B) DMSO tolerance testing. The assay was performed using 
8,000 cells/well and stimulating them with 17-AAG in the presence of 0.1% DMSO (), 0.25 % DMSO (), 0.5 % DMSO (), or 1.0 % 
DMSO () prior to the assay. Data are mean ± SE of n = 8 values. (C) 17-AAG stimulation time. The assay was performed using 8,000 
cells/well and stimulating the cells for 4 (), 6 () or 16 hours (). Data are mean ± SE of n = 8 values. (D) Substrate loading time evalua-
tion. The assay was performed using 8,000 cells/well and 5 hr stimulation in the presence of 0.1 % DMSO and reading the plate at 0.5 (), 1 
(), 1.5 (), 2 () and 3 () hours following substrate addition. Data are mean ± SE of n = 8 values. 
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time of 2 hours or shorter allows for the assay to be conven-
iently performed within the context of an 8-hour workday.  
Assay Miniaturization to 1536-well Plate Format 
 The  HSE-bla assay was further miniaturized into 1536-
well plate format with a final 5 μl assay volume. To check 
the assay quality the assay was tested with a DMSO plate 
containing a final DMSO concentration of 0.46%. In the 
DMSO/CV plate testing, the signal to background ratio (S/B) 
was 3.3 fold, CV was 6.4% and Z’ factor was 0.66 (Fig. 6A). 
Fig. (6B) shows the dose response curve of 17-AAG that 
was generated in 1536-well format, yielding an EC50 of 54 
nM that correlates well with the EC50 (49 nM) obtained in 
384-well format. These results demonstrate that the HSE-bla 
assay can be run in 1536-well format and is robust and suit-
able for high-throughput screening. 
A. DMSO Plate 
 
 
 
 
 
 
 
 
 
 
B. 17-AAG Dose Response 
 
 
 
 
 
 
 
 
 
Fig. (6). Assay miniaturization to 1536-well plate format. (A) Col-
umn 1, dose-response titration of 17-AAG from 0.1 nM to 3.83 M, 
column 2, 600 nM 17-AAG, column 3, 5-48, DMSO, and column 4, 
500 nM 17-AAG. (B) Dose response curve of 17-AAG. 
CONCLUSIONS  
  In conclusion, we have developed a beta-lactamase re-
porter gene assay that can be used for high-throughput 
screening for modulators of the HSR pathway, which can be 
then deconvoluted with lower-throughput follow-up assays, 
such as HSP90 binding assays and/or assays monitoring the 
phosphorylation of HSF1. Taking together the advantages of 
the beta-lactamase reporter technology, which allows for a 
ratiometric and sensitive read-out, this reporter assay can be 
miniaturized to 384-well and 1536-well formats. We have 
demonstrated the suitability of this assay for detecting both 
inducers and inhibitors of HSR signaling using known small 
molecule modulators and HSF-specific RNAi oligos. It is 
anticipated that compound library screening using the HSE-
bla  HeLa assay will provide new leads in the search for 
novel modulators of HSR. 
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